

Global Guillain-Barre Syndrome Drugs Market: Strong Growth Anticipated

The Business Research Company's Guillain-Barre Syndrome Drugs Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, June 20, 2024 /EINPresswire.com/ -- The Guillain-Barre syndrome (GBS) drugs market is poised for significant expansion, growing from \$1.08 billion in 2023 to \$1.17 billion in 2024 at a

CAGR of 7.8%. This growth is driven by advancements in research and development, governmental support, increased focus on neurology and autoimmune diseases, and heightened demand for hospital and clinic services. By 2028, the market is projected to reach \$1.59 billion, expanding at a CAGR of 8.0%.



The Business
Research Company

Guillain-Barre Syndrome Drugs Global Market Report 2024 : Market Size, Trends, And Global Forecast 2024-2033



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs
"

*The Business Research
Company*

Key Drivers and Trends in the Market

Personalized Medicine Propelling Market Growth

The growing demand for personalized medicine is a significant driver of the GBS drugs market. Personalized medicine tailors treatments to individual characteristics, such as genetics and lifestyle, optimizing effectiveness and minimizing adverse effects. In February 2024, the Personalized Medicine Coalition reported that the FDA

approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. This trend is expected to continue, driving further growth in the GBS drugs market.

Explore the global guillain-barre syndrome (gbs) drugs market with a detailed sample report: https://www.thebusinessresearchcompany.com/sample_request?id=15581&type=smp

Innovative Humanized Monoclonal Antibodies

Major companies are focusing on developing innovative products, such as humanized monoclonal antibodies, to maintain their market position. These antibodies are designed to target specific components of the immune system involved in the pathological process of GBS.

Market Segmentation

The GBS drugs market is segmented into the following categories:

By Drug Class

1. Immunoglobulins (IVIG): IVIG is a pooled human blood plasma medication with high antibody concentrations.
2. Corticosteroids
3. Plasma Exchange

By Treatment Type

1. First-Line Treatment
2. Adjunctive or Supportive Treatment

By Application

1. Clinics
2. Hospitals
3. Other Applications

Regional Insights

North America was the largest region in the GBS drugs market in 2023, driven by advanced healthcare infrastructure and significant investment in research and development. However, the Asia-Pacific region is expected to be the fastest-growing market during the forecast period, supported by increasing healthcare expenditures, growing recognition and diagnosis rates of GBS, and expanding geriatric populations.

Major Players in the Market

Key players in the GBS drugs market include:

F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc

Access the complete report for a detailed analysis of the global guillain-barre syndrome (gbs) drugs market:

<https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-drugs-global-market-report>

The Guillain-Barre syndrome drugs market is set for robust growth, fueled by advancements in personalized medicine, innovative therapies such as humanized monoclonal antibodies, and an increasing focus on reducing healthcare costs. With significant investments in research and development and expanding healthcare infrastructures globally, the market is expected to continue its upward trajectory, offering substantial opportunities for key players and new entrants alike.

[Guillain-Barre Syndrome Drugs Global Market Report 2024](#) from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Guillain-Barre Syndrome Drugs Global Market Report 2024 by [The Business Research Company](#) is the most comprehensive report that provides insights on [guillain-barre syndrome drugs market size](#), guillain-barre syndrome drugs market drivers and trends, guillain-barre syndrome drugs market major players, competitors' revenues, market positioning, and market growth across geographies. The guillain-barre syndrome drugs market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Extended-Release Drugs Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report>

Drugs of Abuse (DOA) Testing Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/drugs-of-abuse-doa-testing-global-market-report>

Drugs for Immunotherapy Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report>

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/721463965>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.